BioXcel Therapeutics

2025 marks a pivotal year for life sciences and biotech, with AI in drug discovery, synthetic biology, personalized medicine, cell and gene therapies, and green biotech leading transformative innovations. These advancements promise to revolutionize healthcare, agriculture, and environmental sustainability, despite challenges in accessibility, scalability, and ethics.

The AI in precision medicine market is projected to grow from USD 1.75B in 2024 to USD 37.60B by 2034, with a CAGR of 35.9%. Key segments include deep learning (33.7% share in 2024), software (41.6% share), oncology (31.0% revenue share), and neurology (fastest CAGR of 36.8%). North America leads with a 29.6% revenue share, while Europe is expected to grow at a CAGR of 36.3%. AI integration enhances personalized treatments, early disease detection, and drug development, driving market growth.

The AI in precision medicine market is expected to grow from USD 0.78 billion in 2024 to USD 3.92 billion by 2030, driven by personalized treatments, advanced genomics, and drug development acceleration. AI analyzes complex data for quicker disease identification and tailored therapies, optimizing diagnostics and treatment outcomes. Key players include NVIDIA, Google, Microsoft, and IBM, focusing on innovations like deep learning and AI platforms for drug discovery.

The global AI in precision medicine market is expected to grow from USD 0.78 billion in 2024 to USD 3.92 billion by 2030, driven by the need for customized treatments, advancements in genomics, and the acceleration of drug development. AI's role in analyzing complex data enables quicker disease mechanism identification and tailored therapies. The market sees significant growth in neurology due to the challenges in diagnosing and treating neurological disorders. Key players like NVIDIA, Google, and Microsoft are advancing AI technologies for drug discovery and personalized healthcare, leveraging deep learning models and cloud platforms to enhance treatment predictions and patient outcomes.

BenevolentAI faces challenges with CEO departure and halted program; BioXcel advances BXCL501 in agitation treatments; BullFrog AI shows potential in liver disease and neuropsychiatric conditions; Iktos leverages AI for drug discovery; Jura Bio introduces Variational Synthesis for protein manufacturing; Phare Bio secures funding for AI-driven antibiotic discovery.

The AI in precision medicine market is expected to grow from USD 172.4 million in 2024 to USD 377.1 million by 2029, driven by customized treatments, genomics advancements, and drug development acceleration. Key players include NVIDIA, Google, Microsoft, and others, who use strategies like acquisitions and product innovations to enhance personalized care and treatment predictions.

AI in precision medicine market to reach USD 377.1 million by 2029, driven by advanced technologies and personalized care needs. Software dominates due to data analysis and predictive modeling. Oncology leads in therapeutic areas, aided by AI's ability to interpret complex data. North America leads with sophisticated healthcare systems and significant R&D investments. Key players include NVIDIA, Google, Microsoft, IBM, and Tempus.